Wet Cupping Therapy in Ankylosing Spondylitis
Wet Cupping Therapy in Ankylosing Spondylitis: a Multicenter Randomised Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Karabük, Turkey (Türkiye)
- Karabuk University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Clinical diagnosis of ankylosing spondylitis 18-65 years of age Consent to participate
Exclusion Criteria:
Any ongoing medical treatment other than NSAIDs Pregnancy At least one contraindication to WCT that was detected in subject's history or in the routine blood examinations prior to enrollment (Hgb <9.5; INR> 1.2; history of hemophobia, bleeding disorder, malignant disorder).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Wet cupping arm
This arm is the interventiom group and will receive three consecutive sessions of wet cupping therapy once a month.
|
wet cupping therapy will be applied to participants in this arm for three sessions once a month
|
|
No Intervention: Control arm
This arm is the control group and will not receive any intervention other than the routine medications
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
BASFI
Time Frame: At 0 and 3 months
|
Change in the scores of The Bath Ankylosing Spondylitis Functional Index
|
At 0 and 3 months
|
|
BASDAI
Time Frame: At 0 and 3 months
|
Change in the scores of The Bath Ankylosing Spondylitis Disease Activity Index
|
At 0 and 3 months
|
|
VAS
Time Frame: At 0 and 3 months
|
Change in the scores of Visual Analogue Scale
|
At 0 and 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Schober
Time Frame: At 0 and 3 months
|
Change in the scores of Modified Schober Test
|
At 0 and 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SBU177
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.